CURX Overview

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).

Wall Street analysts forecast CURX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CURX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Curanex Pharmaceuticals Inc revenue for the last quarter amounts to -3.18M USD, increased 2215.98

Curanex Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased

Curanex Pharmaceuticals Inc (CURX) has 6 emplpoyees as of May 27 2026.

Today CURX has the market capitalization of 9.40M USD.